TEM vs TXG
TEM: Tempus AI leverages genomic sequencing, clinical data aggregation, and machine learning to deliver precision oncology diagnostics and AI-powered treatment recommendations that guide cancer patient care. TXG: 10x Genomics provides microfluidic and spatial transcriptomics instruments and consumables that enable researchers to analyze individual cells and tissue architecture at previously inaccessible resolution and scale.
Side-by-side fundamentals
| Metric | TEM | TXG | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $46.96 | $47.05 | |
| Market cap as of 2026-07-23 | $8.4B | $6.0B | |
| Net margin as of 2026-07-23 | -22.2% | -3.5% | TXG higher |
| Gross margin as of 2026-07-23 | +63.4% | +69.7% | TXG higher |
| Operating margin as of 2026-07-23 | -20.6% | -6.1% | TXG higher |
| ROE as of 2026-07-23 | -70.2% | -2.9% | TXG higher |
| ROA as of 2026-07-23 | -14.6% | -2.2% | TXG higher |
| Debt / equity as of 2026-07-23 | 2.96 | 0.00 | TXG lower |
| Revenue growth (YoY) as of 2026-07-23 | +69.8% | +2.3% | TEM higher |
| Revenue CAGR (3y) SEC XBRL | +58.3% | +7.6% | TEM higher |
| Beta as of 2026-07-23 | 2.89 | 2.05 | |
| 1-year return as of 2026-07-22 close | -23.1% | +262.2% | TXG higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.